CureVac
VerifiedDevelops drugs that allow the human body to fight various diseases.
Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$543m (Public information from May 2024)
Share price
$4.34 CVAC
Company register number HRB 754041 (Stuttgart)
Tübingen Baden-Württemberg (HQ)
Deals in current and previous year:
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 181 % | 111 % | (35 %) | (20 %) | 32 % | 39 % | 56 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (225 %) | (375 %) | (331 %) | (439 %) | (277 %) | (121 %) | (43 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (265 %) | (400 %) | (369 %) | (484 %) | (245 %) | (119 %) | (50 %) |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 233 % | 792 % | 93 % | 215 % | - | - | - |
Source: Dealroom estimates
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor investor investor investor | $0.0 | round |
| investor | $0.0 Valuation: $0.0 88.7x EV/LTM Revenues -16.9x EV/LTM EBITDA | round | |
| investor investor | $0.0 Valuation: $0.0 88.7x EV/LTM Revenues -16.9x EV/LTM EBITDA | round | |
| N/A | $0.0 Valuation: $0.0 146.2x EV/LTM Revenues -27.8x EV/LTM EBITDA | round | |
| investor investor | $0.0 | round | |
| N/A | $0.0 | round | |
* | $250m | Post IPO Equity | |
| Total Funding | 000k | ||
RELATED LANDSCAPES AND LISTS
Related Content
Recent News about CureVac
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by CureVac
Edit
ACQUISITION by CureVac Jun 2022